Nathan Brown Interviewed by MCC on FDA and Medical Device Regulatory Regimes

March 19, 2015

Reading Time : 1 min

Contact:

Jacinta O'Shea-Ramdeholl

Director of Communications

Sarah Richmond

Senior Communications Manager

Akin Gump health care and life sciences partner Nathan Brown was interviewed by The Metropolitan Corporate Counsel for its article “Regulation in the Medical Device Industry: FDA insider lays out the issues,” which covered such topics as lessons learned from his time in government (Brown served as special assistant to the chief counsel at the Food and Drug Administration), enforcement regimes, laboratory-developed tests and supply chain integrity.

Brown discussed, among other subjects:

  • Current developments: “The device industry is emerging from a period of significant frustration with the FDA, a high level of distrust and, whether accurate or not, a feeling that the agency’s performance was inconsistent…With more resources now available to the FDA and more formalized procedures, we’ve seen overall improvement in the regulatory environment and in the relationship between the industry and the agency.”
  • Lessons learned from government service: “[I]t is important to keep in mind that various government agencies often pursue different, sometimes even conflicting, yet equally legitimate, missions to meet their core objectives…Companies have to be aware of a matrix of governmental interests as they determine how to advance their own strategy and need to be able to demonstrate somewhat different benefits and results in each case.”
  • State vs. federal enforcement regimes: “Many states have incorporated the Federal Food, Drug, and Cosmetic Act into their own state laws, with the result that its provisions may be enforced at the federal or state levels. In recent years, I have noted increasing instances in which state interpretations of the FD&C Act have deviated from those of the FDA or DOJ, which also enforces the FD&C Act. These potential differences lead to very significant challenges for companies.”

To read the full article, please click here.

Share This Insight

People Mentioned in This News

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.